

**November 13, 2024**

To

**BSE Limited,**

Listing Department, P J Towers,

Dalal Street,

Mumbai – 400 001.

**Scrip code: 540679**

Through: BSE Listing Center

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

**Trading Symbol: SMSLIFE**

Through: NEAPS Portal

**SUB: OUTCOME OF THE 91<sup>ST</sup> BOARD MEETING.**

**Ref: Regulation 23(9), 30 and 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held on today i.e. **November 13, 2024**, have *inter-alia* considered and approved the following:

- i. **Un-audited [Standalone and Consolidated] financial results** for the quarter and half year ended September 30, 2024, as recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of un-audited [Standalone and Consolidated] financial results for the quarter and half year ended September 30, 2024 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results and Statement of Assets & Liabilities & Cash-flow statement.

- ii. **Proposed name change of the Company.**

In this regard, Board has duly considered and approved the proposal for change of the name of the Company as "**HALEOS LABS LIMITED**" contingent upon the approval of the Central Registration Centre, Ministry of Corporate Affairs and other relevant authority(ies), if any.

Further, change is subject to the approval of the shareholders of the Company and subsequent amendment to the Memorandum of Association and Articles of Association of the Company to reflect the name as approved by respective authorities.




- iii. **Related Party Transactions** for the half year ended September 30, 2024, as recommended by the Audit Committee.

In this regard, we are enclosing herewith an excerpt of Related Party Transactions for the half year ended on September 30, 2024, on a consolidated basis, in the format specified under SEBI Circular no. SEBI/HO/CFD/CMDI/CIR/P/2021/662 dated November 22, 2021.

The meeting of the Board commenced at **12.15 pm** and concluded at **2.00 pm**.

**For SMS Lifesciences India Limited**



**Trupti Ranjan Mohanty**

Company Secretary



Please note that this information is submitted to Stock Exchange(s) within 30 mins of the closure of the Board meeting as per the new guidelines prescribed under SEBI (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2023. [Reg. 30(6)]

**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Standalone Statement of Un-audited Financial Results for the Quarter and Half Year Ended 30th September, 2024**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,849.62	8,657.06	6,784.06	16,506.68	14,240.05	30,000.16
2	Other Income	125.58	42.98	33.47	168.56	91.77	383.68
3	<b>Total Revenue</b>	<b>7,975.20</b>	<b>8,700.04</b>	<b>6,817.53</b>	<b>16,675.24</b>	<b>14,331.82</b>	<b>30,383.84</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	3,759.74	4,474.93	3,724.75	8,234.66	8,097.57	16,119.02
	(b) Changes in Inventories	125.67	88.04	(361.58)	213.71	(226.14)	97.57
	(c) Manufacturing Expenses	1,261.64	1,393.78	1,152.08	2,655.42	2,388.00	5,052.92
	(d) Employee Benefits Expense	1,089.82	1,117.93	1,030.95	2,207.75	2,017.90	4,092.41
	(e) Finance Cost	192.46	215.87	247.78	408.34	429.79	890.23
	(f) Depreciation and Amortization Expense	257.07	250.02	255.47	507.09	508.32	1,025.35
	(g) Other Expenses	432.76	205.78	290.61	638.54	503.10	1,195.11
	<b>Total Expenses - (a to g)</b>	<b>7,119.16</b>	<b>7,746.35</b>	<b>6,340.06</b>	<b>14,865.51</b>	<b>13,718.54</b>	<b>28,472.61</b>
5	<b>Profit Before Tax (3-4)</b>	<b>856.04</b>	<b>953.69</b>	<b>477.47</b>	<b>1,809.73</b>	<b>613.28</b>	<b>1,911.23</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	250.00	300.00	140.00	550.00	180.00	425.00
	(ii) Relating to Earlier Year	-	-	-	-	-	(19.75)
	(2) Deferred Tax	5.21	7.70	25.76	12.91	51.52	199.44
		<b>255.21</b>	<b>307.70</b>	<b>165.76</b>	<b>562.91</b>	<b>231.52</b>	<b>604.69</b>
7	<b>Net Profit / (Loss) for the Period (5-6)</b>	<b>600.83</b>	<b>645.99</b>	<b>311.71</b>	<b>1,246.82</b>	<b>381.76</b>	<b>1,306.54</b>
8	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(17.43)	(15.98)	1.93	(33.41)	3.70	(58.11)
	Income Tax effect on the above	(5.07)	(4.65)	0.56	(9.73)	1.08	(16.92)
		<b>(12.36)</b>	<b>(11.33)</b>	<b>1.37</b>	<b>(23.68)</b>	<b>2.62</b>	<b>(41.19)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>588.47</b>	<b>634.66</b>	<b>313.08</b>	<b>1,223.14</b>	<b>384.38</b>	<b>1,265.35</b>
10	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	<b>19.87</b>	<b>21.37</b>	<b>10.31</b>	<b>41.24</b>	<b>12.63</b>	<b>43.22</b>
	Paid-up equity share capital (Face Value of Rs.10/- each)	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						17,320.48

For SMS Lifesciences India Limited

TVSN-Murthy  
Managing Director  
DIN:00465198



**Standalone Un-Audited Statement of Assets and Liabilities as at 30th September, 2024**

(Rs.in Lakms)

Sr. No.	Particulars	As at	As at
		30.09.2024 (Un Audited)	31.03.2024 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	13,229.96	13,578.39
	(b) Right-of-use Assets	208.93	240.28
	(c) Capital Work-in-Progress	1,277.81	600.11
	(d) Intangible Assets	2.39	4.08
	(e) Financial Assets:		
	(i) Investments	2,323.17	2,323.17
	(ii) Other Financial Assets	270.93	270.81
	(f) Other Non-Current Assets	347.05	271.55
	<b>Sub Total :Non-Current Assets</b>	<b>17,660.24</b>	<b>17,288.39</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	6,278.19	7,458.87
	(b) Financial Assets		
	(i) Trade Receivables	6,862.78	4,934.69
	(ii) Cash and Cash Equivalents	13.75	33.49
	(iii) Bank Balances (Other than (ii) above)	92.44	92.30
	(c) Other Current Assets	4,641.42	4,929.99
	<b>Sub Total : Current Assets</b>	<b>17,888.58</b>	<b>17,449.34</b>
	<b>TOTAL ASSETS</b>	<b>35,548.82</b>	<b>34,737.72</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	18,498.26	17,320.48
	<b>Sub-Total -Smareolders' funds</b>	<b>18,800.59</b>	<b>17,622.81</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	2,255.80	2,831.41
	(ii) Lease Liabilities	205.73	239.39
	(b) Provisions	433.63	401.63
	(c) Deferred Tax Liabilities (net)	1,375.44	1,372.26
	<b>Sub-Total -Non-Current Liabilities</b>	<b>4,270.60</b>	<b>4,844.69</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	6,015.69	6,041.48
	(ii) Lease Liabilities	65.47	61.86
	(iii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	183.29	76.57
	(b) Dues to Creditors other than Micro & Small Enterprises	4,632.40	4,877.21
	(iv) Other Financial Liabilities	796.66	697.63
	(b) Provisions	171.62	163.62
	(c) Other Current Liabilities	345.43	345.70
	(d) Current Tax Liabilities (Net)	267.07	6.16
	<b>Sub-Total - Current Liabilities</b>	<b>12,477.63</b>	<b>12,270.23</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>35,548.82</b>	<b>34,737.73</b>

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198

**SMS LifeSciences India Limited**  
**Standalone Statement of Cash Flow for the Half Year Ended 30th September, 2024**  
(All amounts in Indian Rupees, unless otherwise stated)

Particulars	For the Half Year ended 30th Sept, 2024	For the Year ended 31st March, 2024
<b>A Cash Flow from Operating Activities</b>		
Profit Before Income Tax	1,809.73	1,911.23
<b>Adjustments for:</b>		
Depreciation and amortisation expense	507.09	1,025.35
Interest Income classified as Investing Cash Flows	(2.92)	(5.74)
Allowance for Doubtful Debts	72.32	4.83
Interest on Non Current Borrowings	171.29	429.48
Interest on Unsecured Loans	-	9.53
Provision for Employee Benefits	6.59	16.69
Term Loan Processing Fee	1.77	3.54
Loss on Sale of Assets	1.03	0.18
Interest on Leased Premises	16.45	56.02
	<b>2,583.35</b>	<b>3,451.10</b>
<b>Change in Operating Assets and Liabilities</b>		
(Increase)/Decrease in Trade Receivables	(2,000.41)	(387.64)
(Increase)/Decrease in Inventories	1,180.68	587.35
Increase/(Decrease) in Trade Payables	(138.08)	(498.76)
(Increase)/Decrease in Other Non Current Financial Assets	(0.12)	(9.14)
(Increase)/Decrease in Other Non Current Asset	(75.50)	76.43
(Increase)/Decrease in Other Current Financial Assets	0.16	(0.23)
(Increase)/Decrease in Other Current Asset	288.57	(927.77)
(Increase) Decrease in Prepaid Taxes	(89.09)	(35.54)
Increase/(Decrease) in Other Current Financial Liabilities	(11.33)	19.47
Increase/(Decrease) in Other Current Liabilities	(0.27)	(500.13)
	<b>(845.39)</b>	<b>(1,675.96)</b>
<b>Cash generated from Operations</b>	1,737.96	1,775.14
Income Taxes Paid	(200.00)	(300.00)
<b>Net Cash Inflow from Operating Activities "A"</b>	<b>1,537.96</b>	<b>1,475.14</b>
<b>B Cash flows from Investing Activities</b>		
Purchase for Property, Plant and Equipment	(688.44)	(1,371.95)
Proceeds from sale of Property, Plant and Equipment	4.75	3.03
Margin Money Deposits	2.32	(11.56)
Interest Received on Margin Money Deposit	0.30	5.53
<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(681.07)</b>	<b>(1,374.95)</b>
<b>C Cash flows from Financing Activities</b>		
Proceeds from Long Term Borrowings	-	-
Repayment of Long Term Borrowings	(681.84)	(949.84)
Proceeds from Short Term Borrowings	78.66	1,664.73
Repayment of Short term Borrowings		
Repayment of Lease Liability	(30.05)	115.92
Interest paid	(198.05)	(507.29)
Repayment of Unsecured Loan	-	(360.00)
Dividend paid to company's shareholders	(45.35)	(45.35)
<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>(876.63)</b>	<b>(81.83)</b>
<b>Net Increase (Decrease) in Cash and Cash</b>		
<b>Equivalents (A+B+C)</b>	<b>(19.74)</b>	<b>18.35</b>
Cash and Cash Equivalents at the beginning of the Financial Year / Period	33.49	15.14
<b>Cash and Cash Equivalents at End of the Year / Period</b>	<b>13.75</b>	<b>33.49</b>

**For SMS Lifesciences India Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN:00465198**



**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 13th November, 2024 and have been approved by the Board of Directors at its meeting held on 13th November, 2024. The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter and half year ended 30th September, 2024 and expressed unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 13-11-2024

For SMS Lifesciences India Limited

  
TVVSN Murthy  
Managing Director  
DIN:00465198

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to  
The Board of Directors  
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **SMS Lifesciences India Limited** ("the Company"), for the quarter ended 30<sup>th</sup> September 2024 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 13.11.2024

UDIN:24026548BKAMVT1841

For Rambabu & Co.,  
Chartered Accountants  
Reg. No:002976S

  
GVL Prasad  
Partner  
M.No. 026548





**SMS LIFESCENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of Un-audited Financial Results for the Quarter and Half Year Ended 30th September, 2024**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,846.19	9,254.82	6,926.11	17,101.01	16,008.08	30,595.84
2	Other Income	203.85	42.57	33.59	246.42	94.98	382.81
3	<b>Total Revenue</b>	<b>8,050.04</b>	<b>9,297.39</b>	<b>6,959.70</b>	<b>17,347.43</b>	<b>16,103.06</b>	<b>30,978.65</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	3,501.48	4,272.12	3,574.83	7,773.60	9,369.54	15,018.83
	(b) Changes in Inventories	76.07	59.56	(349.08)	135.62	(144.48)	97.32
	(c) Manufacturing Expenses	1,469.39	1,633.59	1,294.37	3,102.98	2,647.68	5,763.11
	(d) Employee Benefits Expense	1,408.77	1,437.91	1,302.26	2,846.68	2,545.59	5,225.84
	(e) Finance Cost	213.55	240.48	280.57	454.03	498.13	1,015.67
	(f) Depreciation and Amortization Expense	376.26	367.87	373.44	744.14	742.98	1,493.76
	(g) Other Expenses	534.12	221.83	317.33	755.95	550.18	1,379.45
	<b>Total Expenses - (a to g)</b>	<b>7,579.64</b>	<b>8,233.36</b>	<b>6,793.71</b>	<b>15,813.00</b>	<b>16,209.62</b>	<b>29,993.98</b>
5	<b>Profit Before Tax (3-4)</b>	<b>470.40</b>	<b>1,064.03</b>	<b>165.99</b>	<b>1,534.43</b>	<b>(106.56)</b>	<b>984.67</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	238.00	312.00	140.00	550.00	180.00	425.00
	(ii) Relating to Earlier Year	-	-	-	-	-	(19.75)
	(2) Deferred Tax	(97.63)	42.40	70.24	(55.23)	140.46	(53.36)
		<b>140.37</b>	<b>354.40</b>	<b>210.24</b>	<b>494.77</b>	<b>320.46</b>	<b>351.89</b>
7	<b>Net Profit / (Loss) for the Period (5-6)</b>	<b>330.03</b>	<b>709.63</b>	<b>(44.25)</b>	<b>1,039.66</b>	<b>(427.02)</b>	<b>632.78</b>
8	<b>Other Comprehensive Income/(Loss) (OCI):</b>						
	(A) Items that will not be reclassified to statement of Profit & Loss						
	Remeasurement of post-employment benefit obligations	(19.17)	(17.56)	0.98	(36.73)	1.88	(63.86)
9	Income Tax effect on the above	(5.53)	(5.06)	0.32	(10.59)	0.60	(18.42)
10	<b>Other Comprehensive Income/(Loss) after tax for the Period / Year (8-9)</b>	<b>(13.64)</b>	<b>(12.50)</b>	<b>0.66</b>	<b>(26.14)</b>	<b>1.28</b>	<b>(45.44)</b>
11	<b>Total comprehensive Income for the period/year (9+12)</b>	<b>316.39</b>	<b>697.13</b>	<b>(43.59)</b>	<b>1,013.52</b>	<b>(425.74)</b>	<b>587.34</b>
	<b>Profit for the year attributable to:</b>						
	Equity holders of the parent	467.26	699.81	67.86	1,167.07	(111.53)	909.28
	Non-controlling interests	(137.23)	9.82	(112.12)	(127.41)	(315.49)	(276.50)
	<b>Total comprehensive income for the year attributable to:</b>						
	Equity holders of the parent	454.14	687.78	68.81	1,141.91	(109.71)	865.54
	Non-controlling interests	(137.75)	9.35	(112.40)	(128.39)	(316.03)	(278.20)
12	Earning Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	15.46	23.15	2.24	38.60	(3.69)	30.08
13	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
14	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						17,379.09

For SMS Lifesciences India Limited

TVYSN Murthy  
Managing Director  
DIN:00465198



**Consolidated Statement of Assets and Liabilities as at 30th September, 2024**

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		30.09.2024 (Un Audited)	31.03.2024 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	21,515.80	22,088.61
	(b) Right-of-use Assets	208.93	240.28
	(c) Capital Work-in-Progress	1,277.81	600.11
	(d) Intangible Assets	3.19	4.96
	(e) Financial Assets:		
	(i) Investments	3.61	3.61
	(ii) Other Financial Assets	313.92	313.80
	(f) Other Non-Current Assets	347.05	273.34
	<b>Sub Total :Non-Current Assets</b>	<b>23,670.31</b>	<b>23,524.69</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	7,109.13	8,121.04
	(b) Financial Assets		
	(i) Trade Receivables	7,121.64	5,135.05
	(ii) Cash and Cash Equivalents	26.79	56.95
	(iii) Bank Balances (Other than (ii) above)	92.44	92.30
	(c) Other Current Assets	1,120.02	2,116.89
	(d) Current Tax Assets (Net)	-	5.01
	<b>Sub Total : Current Assets</b>	<b>15,470.02</b>	<b>15,527.24</b>
	<b>TOTAL ASSETS</b>	<b>39,140.33</b>	<b>39,051.93</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	18,475.65	17,379.09
	<b>Equity Attributable to Share Holders of the company</b>	<b>18,777.98</b>	<b>17,681.42</b>
	Non Cotroling Interest	1,553.85	1,682.24
	<b>Sub-Total -Shareholders' funds</b>	<b>20,331.83</b>	<b>19,363.66</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	2,545.21	3,314.50
	(ii) Lease Liabilities	205.73	239.39
	(b) Provisions	520.64	474.12
	(c) Deferred Tax Liabilities (Net)	1,138.54	1,204.37
	<b>Sub-Total -Non-Current Liabilities</b>	<b>4,410.12</b>	<b>5,232.38</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	6,404.17	6,456.63
	(ii) Lease Liabilities	65.47	61.86
	(iii) Trade Payables:		
	(a) Trade Payables - Micro & Small Enterprises	212.83	78.38
	(b) Trade Payables - otherthan Micro & Small Enterprises	5,405.41	5,834.27
	(iv) Other Financial Liabilities	935.28	873.26
	(b) Provisions	174.43	165.95
	(c) Other Current Liabilities	970.05	985.54
	(d) Current Tax Liabilities (Net)	230.74	-
	<b>Sub-Total - Current Liabilities</b>	<b>14,398.38</b>	<b>14,455.89</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>39,140.33</b>	<b>39,051.93</b>

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198

# SMS LifeSciences India Limited

Consolidated Statement of Cash Flow for the Half Year Ended 30th September, 2024.

(All amounts in Indian Rupees, unless otherwise stated)

Particulars	For the Half Year ended 30.09.2024	For the Year ended 31.03.2024
<b>A Cash Flow from Operating Activities</b>		
Profit Before Income Tax	1,534.43	984.67
<b>Adjustments for:</b>		
Depreciation and amortisation expense	744.14	1,493.76
Interest Income classified as Investing Cash Flows	(2.92)	(8.01)
Allowance for Doubtful Debts	72.32	4.83
Interest on Non Current Borrowings	215.90	551.53
Interest on Unsecured Loans	-	9.53
Provision for Employee Benefits	18.27	36.13
Term Loan Processing Fee	2.32	4.65
Profit on Sale of Assets	-	(0.10)
Loss on Sale of Assets	1.03	0.18
Notional Rent Expense	-	-
Interest On Leased Premises	16.45	56.03
	<b>2,601.94</b>	<b>3,133.18</b>
<b>Change in Operating Assets and Liabilities</b>		
(Increase)/Decrease in Trade Receivables	(2,058.92)	(533.77)
(Increase)/Decrease in Inventories	1,011.91	502.45
Increase/(Decrease) in Trade Payables	(306.50)	(21.79)
(Increase)/Decrease in Other Non Current Financial Assets	(0.12)	(9.14)
(Increase)/Decrease in Other Non Current Asset	(73.71)	74.64
(Increase)/Decrease in Other Current Financial Assets	0.16	(0.24)
(Increase)/Decrease in Other Current Asset	(3,418.66)	(4,036.97)
(Increase) Decrease in Prepaid Taxes	(114.25)	(29.33)
Increase/(Decrease) in Other Current Financial Liabilities	(11.33)	19.47
Increase/(Decrease) in Other Current Liabilities	4,400.05	3,632.05
	<b>(571.37)</b>	<b>(402.63)</b>
<b>Cash generated from Operations</b>	2,030.57	2,730.55
Income Taxes Paid	(200.00)	(300.00)
<b>Net Cash Inflow from Operating Activities "A"</b>	<b>1,830.57</b>	<b>2,430.55</b>
<b>B Cash flows from Investing Activities</b>		
Purchase for Property, Plant and Equipment	(725.96)	(2,086.77)
Proceeds from sale of Property, Plant and Equipment	4.75	12.29
Proceeds from sale of Investments	-	-
Margin Money Deposits	2.32	(11.56)
Fixed Deposits Made	-	233.21
Interest Received on Margin Money Deposit	0.30	7.80
<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(718.59)</b>	<b>(1,845.03)</b>
<b>C Cash flows from Financing Activities</b>		
Proceeds from Long Term Borrowings	-	-
Repayment of Long Term Borrowings	(902.74)	(1,402.31)
Proceeds from Short Term Borrowings	78.67	1,664.73
Repayment of Lease Liability	(30.05)	115.92
Interest paid	(242.66)	(629.35)
Repayment of Unsecured Loan	-	(360.00)
Dividend paid to company's shareholders	(45.35)	(45.35)
<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>(1,142.13)</b>	<b>(656.36)</b>
<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(30.15)</b>	<b>(70.83)</b>
Cash and Cash Equivalents at the beginning of the Financial Year	56.95	127.78
<b>Cash and Cash Equivalents at End of the Period / Year</b>	<b>26.80</b>	<b>56.95</b>

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198



**Notes:**

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 13th November, 2024 and have been approved by the Board of Directors at its meeting held on 13th November, 2024. The statutory auditors of the Company have carried out the limited review of Consolidated financial results for the quarter and half year ended 30th September, 2024 and expressed unmodified conclusion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary with 60% stake.
- 4 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 13-11-2024

For SMS Lifesciences India Limited

TVSN Murthy  
Managing Director  
DIN:00465198



**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
**SMS Lifesciences India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SMS Lifesciences India Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> September, 2024 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. M/s.SMS Lifesciences India Limited
- b. M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.532.61 Lakhs, total net loss after tax of Rs.343.08 Lakhs and total comprehensive Loss of Rs.344.37 Lakhs for the Quarter ended 30 September, 2024, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 13.11.2024

UDIN:24026548BKAMVU5225

For Rambabu & Co.,


Chartered Accountants

Reg. No.0029765

GVL Prasad

Partner

M. No. 026548





## Consolidated Related Party Disclosure for the half year ended Sept 30, 2024

[Reg. 23 (9) of the SEBI (Listing Obligations &amp; Disclosure Requirements) Regulations, 2015

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be

S.No	Details of the Party (listed entity / subsidiary) entering in to the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Ref - Note 1)	Value of transaction during reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN (Ref - Note 3)	Name	PAN (Ref - Note 3)	Relationship of the counterparty with the listed entity or its subsidiary				Opening Balance	Closing Balance	Nature of indebtedness	Cost	Tenure	Nature (loans/advance/inter-corporate deposit/investment)	Interest rate (%)	Tenure	Secured/Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)		
1	SMS Lifesciences India Limited		Purogene Labs Private Limited (Ref - Note 6)		Enterprises over which Directors or their relatives exercise significant influence	Purchases of Goods & Services	4,000.00	817.83	316.41	-124.37	-	-	-	-	-	-	-			
2						Sale of Goods & Services	3,000.00	264.97	-	-	-	-	-	-	-	-	-	-	-	-
3						Rent received	10.00	1.94	-	-	-	-	-	-	-	-	-	-	-	-
4			Mahi Drugs Private Limited		Material Subsidiary		Purchases of Goods & Services	5,500.00	1,081.28	3,202.85	3,809.20	-	-	-	-	-	-	-		
5							Sale of Goods & Services	3,000.00	185.10	-	-	-	-	-	-	-	-	-	-	-
6							Rent received	10.00	2.92	-	-	-	-	-	-	-	-	-	-	-
7			SMS Pharmaceuticals Ltd		Other Related Party		Purchases of Goods & Services	500.00	1.11	-	-	-	-	-	-	-	-	-		
							Sale of Goods & Services	2,000.00	1,341.68	418.12	1,190.68	-	-	-	-	-	-	-	-	
8			SMS Lifesciences India Limited		ChemWerth Inc, USA		Other Related Party	Sale of Goods & Services	2,000.00	20.88	57.97	-99.52	-	-	-	-	-	-		
9					TVVSN Murthy	-	Key Management Personnel	Remuneration	101.97	100.32	7.29	7.20	-	-	-	-	-	-	-	
10					N Rajendra Prasad	-	Key Management Personnel		10.01	10.01	1.13	1.26	-	-	-	-	-	-	-	
11					Trupti Ranjan Mohanty	-	Key Management Personnel		7.13	7.13	0.92	1.00	-	-	-	-	-	-	-	
12					T V Praveen	-	Executive Director		36.00	36.00	3.52	3.52	-	-	-	-	-	-	-	
13					G Sudeepthi	-	Whole Time Director		12.00	12.00	1.45	1.85	-	-	-	-	-	-	-	
14					P Sarath Kumar	-	Independent Director	Sitting Fee	-	2.30	-	-	-	-	-	-	-	-	-	
15					Mannam Malakondaiah	-	Independent Director		-	2.30	-	-	-	-	-	-	-	-	-	
16	Srinivasa Samavedam	-			Independent Director	-	1.45		-	-	-	-	-	-	-	-	-			
17	Mahi Drugs Private Limited				Purogene Labs Private Limited (Ref - Note 6)		Enterprises over which Directors or their relatives exercise significant influence	Purchases of Goods & Services	500.00	-	-5.55	-	-	-	-	-	-	-		
18			ChemWerth Inc, USA	-	Other Related Party	Sale of Goods & Services	3,500.00	82.65	-551.45	-590.01	-	-	-	-	-	-				
19			SMS Pharmaceuticals Ltd		Other Related Party	Purchases of Goods & Services	25.00	1.37	-	-	-	-	-	-	-	-				
20						Sale of Goods & Services	500.00	108.05	27.83	69.63	-	-	-	-	-	-	-			
<b>Total</b>							<b>4,081.29</b>													

## Note:

- The value of the related party transactions denotes the amount approved by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company and the subsidiary, as the case may be, for the year 2024-25.
- Purchase / Sale of Goods & Services were approved individually by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company. However, for reporting purpose the same has been clubbed.
- As per the guidance note for disclosure of Related Party Transactions dated April 25, 2022, issued by the Stock Exchanges, since the Company is filing this disclosure in PDF format, the PAN details are not to be included in the disclosure. (XBRL is filed separately along with PAN)
- Aforesaid transactions with related parties are in the ordinary course of business and in arm's length basis.
- Sitting fees paid to Independent Directors is treated as "Related Party Transactions" based on the guidelines of INDAS -24.
- Formerly known as "R-Chem (Somnaballi) Private Limited" (Name has changed vide MCA approval w.e.f. 09.02.2024)

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198